Broadcom named strategic vendor for Walmart virtualization solutions
PRINCETON, N.J. - Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported first quarter earnings that fell short of analyst expectations on Monday.
The company’s shares were down -4.75% in premarket trading following the release.
The medical technology company posted adjusted earnings per share of $0.41, missing the consensus estimate of $0.56. Revenue came in at $382.7 million, below analyst projections of $411.65 million.
Compared to the same quarter last year, revenue increased 3.7% on a reported basis but declined 3.5% organically. The company cited shipping holds across several product lines as a key factor impacting sales.
"We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational excellence," said Mojdeh Poul, president and chief executive officer. "There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive Compliance Master Plan and build a foundation for sustainable performance."
For the second quarter, Integra expects revenue between $390 million and $400 million, representing a reported decline of 6.8% to 4.4% YoY. The company reaffirmed its full-year 2025 revenue guidance range but reduced its adjusted EPS outlook to $2.19-$2.29 per share, citing a $0.22 per share impact from new tariffs.
Integra ended the quarter with $273 million in cash plus short-term investments. The company’s net debt stood at $1.57 billion as of March 31, 2025.
While facing near-term headwinds, management expressed optimism about the long-term growth potential of Integra’s product portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.